Aleix Prat

About me

Featured publications

• A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

  Authors: Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS .

  Reference: Clinical Cancer Research 2020.

• Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

  Authors: Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A .

  Reference: Clinical Cancer Research 2020.

• Immune-related adverse events of checkpoint inhibitors

  Authors: Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME .

  Reference: Nature Reviews Disease Primers 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Authors: Schettini F; Pascual T; Conte B; Chic N; Brasó-Maristany F; Galván P; Martínez O; Adamo B; Vidal M; Muñoz M; Fernández-Martinez A; Rognoni C; Griguolo G; Guarneri V; Conte PF; Locci M; Brase JC; Gonzalez-Farre B; Villagrasa P; De Placido S; Schiff R; Veeraraghavan J; Rimawi MF; Osborne CK; Pernas S; Perou CM; Carey LA; Prat A.

  Reference: Cancer Treatment Reviews 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Authors: Brasó-Maristany F., Griguolo G., Pascual T., Paré L., Nuciforo P., Llombart-Cussac A., Bermejo B., Oliveira M., Morales S., Martínez N., Vidal M., Adamo B., Martínez O., Pernas S., López R., Muñoz M., Chic N., Galván P., Garau I., Manso L., Alarcón J., Martínez E., Gregorio S., Gomis R.R., Villagrasa P., Cortés J., Ciruelos E., Prat A..

  Reference: Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Authors: Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J .

  Reference: Lancet Oncology 2020.

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  Authors: Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; DIeci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.

  Reference: Journal Of The National Cancer Institute 2020.

• A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

  Authors: Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R .

  Reference: Annals Of Oncology 2019.

Featured Projects

• Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

  Principal investigator: Aleix Prat Aparicio

  Funder: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede)

  Code: 201935-30-31-32

  Duration: 30/07/2020 - 29/07/2023

  Web: https://www.ccma.cat/324/15-068-252-euros-record-historic-del-marcador-final-de-la-marato-2018/noticia/2927270/

• Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

  Principal investigator: Aleix Prat Aparicio

  Funder: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Partic

  Code: GCAEC19010PRAT

  Duration: 01/12/2019 - 30/11/2024

• AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer

  Principal investigator: Patricia Galvan, Aleix Prat Aparicio

  Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research

  Code: BCRF_AACR_18_001

  Duration: 01/07/2019 - 30/06/2021

• Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

  Principal investigator: Aleix Prat Aparicio

  Code: 19-IO-011

  Duration: 01/07/2019 - 30/06/2021

• Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk

  Principal investigator: Aleix Prat Aparicio

  Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundación Quiron Salaud ; Fundación Quirón Salud

  Code: TERAPIA_AMIGOS_18_01

  Duration: 11/02/2019 - 10/02/2022